Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.Quarterly revenue came in at$744.86 million, beating the consensus estimate of $683.36 million.According to Sarepta CEO Doug Ingram, the company also faced headwinds in the quarter. “While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to$2.3 billion to $2.6 billion,” Ingra ...